James Claudine G, Ulici Veronica, Tuckermann Jan, Underhill T Michael, Beier Frank
CIHR Group in Skeletal Development and Remodelling, Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
BMC Genomics. 2007 Jul 1;8:205. doi: 10.1186/1471-2164-8-205.
Glucocorticoids (GCs) are widely used anti-inflammatory drugs. While useful in clinical practice, patients taking GCs often suffer from skeletal side effects including growth retardation in children and adolescents, and decreased bone quality in adults. On a physiological level, GCs have been implicated in the regulation of chondrogenesis and osteoblast differentiation, as well as maintaining homeostasis in cartilage and bone. We identified the glucocorticoid receptor (GR) as a potential regulator of chondrocyte hypertrophy in a microarray screen of primary limb bud mesenchyme micromass cultures. Some targets of GC regulation in chondrogenesis are known, but the global effects of pharmacological GC doses on chondrocyte gene expression have not been comprehensively evaluated.
This study systematically identifies a spectrum of GC target genes in embryonic growth plate chondrocytes treated with a synthetic GR agonist, dexamethasone (DEX), at 6 and 24 hrs. Conventional analysis of this data set and gene set enrichment analysis (GSEA) was performed. Transcripts associated with metabolism were enriched in the DEX condition along with extracellular matrix genes. In contrast, a subset of growth factors and cytokines were negatively correlated with DEX treatment. Comparing DEX-induced gene expression data to developmental changes in gene expression in micromass cultures revealed an additional layer of complexity in which DEX maintains the expression of certain chondrocyte marker genes while inhibiting factors that promote vascularization and ultimately ossification of the cartilaginous template.
Together, these results provide insight into the mechanisms and major molecular classes functioning downstream of DEX in primary chondrocytes. In addition, comparison of our data with microarray studies of DEX treatment in other cell types demonstrated that the majority of DEX effects are tissue-specific. This study provides novel insights into the effects of pharmacological GC on chondrocyte gene transcription and establishes the foundation for subsequent functional studies.
糖皮质激素(GCs)是广泛使用的抗炎药物。虽然在临床实践中很有用,但服用GCs的患者常遭受骨骼方面的副作用,包括儿童和青少年生长发育迟缓,以及成年人骨质下降。在生理层面,GCs参与软骨形成和成骨细胞分化的调节,以及维持软骨和骨骼的内环境稳定。在原代肢芽间充质微团培养物的微阵列筛选中,我们将糖皮质激素受体(GR)鉴定为软骨细胞肥大的潜在调节因子。GCs在软骨形成中的一些调控靶点是已知的,但药理剂量的GCs对软骨细胞基因表达的整体影响尚未得到全面评估。
本研究系统地鉴定了在6小时和24小时用合成GR激动剂地塞米松(DEX)处理的胚胎生长板软骨细胞中的一系列GC靶点基因。对该数据集进行了常规分析和基因集富集分析(GSEA)。与代谢相关的转录本以及细胞外基质基因在DEX处理条件下富集。相反,一部分生长因子和细胞因子与DEX处理呈负相关。将DEX诱导的基因表达数据与微团培养物中基因表达的发育变化进行比较,揭示了另一层复杂性,即DEX维持某些软骨细胞标记基因的表达,同时抑制促进血管化并最终导致软骨模板骨化的因子。
总之,这些结果为DEX在原代软骨细胞中发挥作用的机制和主要分子类别提供了见解。此外,将我们的数据与其他细胞类型中DEX处理的微阵列研究进行比较表明,DEX的大多数作用具有组织特异性。本研究为药理GC对软骨细胞基因转录的影响提供了新的见解,并为后续功能研究奠定了基础。